CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenue	$ 4,346	$ 9,282	$ 9,509	$ 13,679
Costs and expenses:
Cost of revenue	654	848	2,087	2,698
Research and development	5,956	23,876	24,560	71,738
General and administrative	5,653	7,091	17,249	24,198
Licensing	1,754	7,344	4,070	8,955
Revaluation of contingent consideration	800	1,700	3,800	(600)
Total costs and expenses	14,817	40,859	51,766	106,989
Loss from operations	(10,471)	(31,577)	(42,257)	(93,310)
Other income:
Interest income	1,991	2,316	5,850	6,320
Non-cash royalty income	894		894
Total other income	2,885	2,316	6,744	6,320
Net loss	$ (7,586)	$ (29,261)	$ (35,513)	$ (86,990)
Net loss per share, basic	$ (0.11)	$ (0.41)	$ (0.50)	$ (1.25)
Net loss per share, diluted	$ (0.11)	$ (0.41)	$ (0.50)	$ (1.25)
Weighted average common shares outstanding, basic	71,381,731	70,807,934	71,249,813	69,452,495
Weighted average common shares outstanding, diluted	71,381,731	70,807,934	71,249,813	69,452,495
Other comprehensive loss:
Unrealized gain (loss) on marketable securities, net of tax of $0	$ 890	$ (18)	$ 533	$ (232)
Total other comprehensive gain (loss)	890	(18)	533	(232)
Comprehensive loss	(6,696)	(29,279)	(34,980)	(87,222)
Contract research
Revenues:
Total revenue	645	705	1,926	2,469
Licensing
Revenues:
Total revenue	$ 3,701	$ 8,577	$ 7,583	$ 11,210